Skip to content

NMN Side Effects: What the Research Actually Shows

By · Updated 26 October 2026 · 8 min read

NMN molecular mechanism — how nicotinamide mononucleotide boosts NAD+ levels

Before starting any supplement, asking about safety and side effects is not only reasonable — it is essential. NMN (nicotinamide mononucleotide) has attracted considerable scientific and consumer interest as a NAD+ precursor linked to healthy ageing, energy metabolism, and cellular repair. But what does the evidence actually say about how safe it is? This article reviews the published clinical trial data on NMN side effects, identifies who should exercise caution, and explains what doses have been studied in human trials to date.

The Short Answer: Is NMN Safe?

Based on current human clinical trial data, NMN appears to be safe and well-tolerated at standard supplementation doses of 250 to 500mg per day. No serious adverse events — including liver toxicity, kidney damage, or cardiovascular harm — have been reported in any published human trial to date.

That said, it is important to be clear about the limits of the evidence. Most published randomised controlled trials of NMN in humans have run for 12 weeks or less. There are no multi-year safety datasets for NMN supplementation of the kind that exist for more established nutrients. NMN is sold as a food supplement — not a licensed medicine — and it has not undergone the multi-phase clinical approval process that pharmaceutical drugs must pass through before reaching the market.

This does not mean NMN is unsafe. Biosynthetically, NMN is a naturally occurring molecule found in small amounts in foods such as edamame, broccoli, cucumber, and avocado. Supplemental NMN simply delivers a much higher concentration of a compound your body already produces and uses. However, honest communication about what the science currently confirms — and what remains unknown — is part of how we think responsible supplementation should work.

Human Clinical Trial Safety Data

Several human clinical trials have specifically evaluated the safety profile of NMN supplementation. Here is a summary of the key published studies:

Yoshino et al. (2021, Science): This landmark trial enrolled 25 post-menopausal women with prediabetes and supplemented them with 250mg of NMN per day for 10 weeks. No adverse events were reported. The study found improvements in skeletal muscle insulin signalling, and safety monitoring showed no abnormalities in liver enzymes, kidney function markers, or haematological parameters.

Igarashi et al. (2022, npj Aging): This placebo-controlled trial gave healthy older men 250mg of NMN per day for up to 12 weeks. Supplementation was well tolerated with no significant harmful effects, and blood NAD+ levels rose significantly.

Liao et al. (2021): This randomised, double-blind trial in China assigned 48 amateur runners to placebo or 300mg, 600mg or 1,200mg of NMN per day for six weeks, alongside exercise training. No serious adverse events were reported at any dose, including 1,200mg per day — far above standard supplementation.

Fukamizu et al. (2022, Scientific Reports): A randomised, placebo-controlled safety study gave 31 healthy men and women aged 20–65 a single daily dose of 1,250mg of NMN for up to four weeks. Blood, urine and body-composition tests stayed within normal physiological variation and no severe adverse events occurred. Two other 12-week trials at 250mg per day also reported no safety concerns (Okabe et al., 2022; Kim et al., 2022).

Across all published human studies to date, no trial has found evidence of hepatotoxicity (liver toxicity), nephrotoxicity (kidney damage), or cardiovascular harm attributable to NMN supplementation. This is a meaningful finding, given that liver and kidney toxicity are the most common safety concerns with novel supplements.

Reported Side Effects (Mild and Rare)

While clinical trials have not documented significant side effects, anecdotal reports from users provide a picture of the mild, occasional effects that some people notice — particularly when starting out or taking higher doses.

Gastrointestinal discomfort: Some users report mild bloating, nausea, or stomach sensitivity, particularly at doses above 500mg per day. This is the most frequently mentioned side effect in user reports and online supplement communities. The straightforward solution is to take NMN with food, which appears to significantly reduce GI sensitivity. If you are starting at 500mg and experiencing discomfort, trying 250mg for the first two to four weeks before increasing is a sensible approach.

Vivid dreams or sleep disruption: A subset of users report unusually vivid dreams or mild difficulty falling asleep when taking NMN in the evening. This is plausibly related to NMN's role in supporting cellular energy metabolism — taking something that promotes energy production close to bedtime may conflict with the body's wind-down process. The practical fix is straightforward: take NMN in the morning. The majority of experienced NMN users dose in the morning for this reason, and the issue resolves for most people who make that switch.

It bears repeating that these effects are anecdotal, not documented in controlled clinical trials. They are not universal, and many users — including those taking 500mg daily — report no side effects at all. Individual variation in gut sensitivity, circadian sensitivity, and metabolic response means that experiences differ significantly from person to person.

Who Should Be Cautious

For the majority of healthy adults, NMN supplementation carries a low risk profile based on current evidence. There are, however, specific groups who should exercise caution or seek medical advice before supplementing:

People with active cancer or a history of cancer: This is the most important caution in the NMN safety discussion. NAD+ plays a fundamental role in cellular energy metabolism, and cancer cells have an elevated demand for NAD+ to fuel rapid proliferation. Some preclinical research — primarily in animal models and cell lines — suggests that elevating NAD+ levels may support cancer cell growth. This does not mean NMN causes cancer; it is not a carcinogen. But for anyone with a current cancer diagnosis or a history of cancer treatment, discussing NMN supplementation with your oncologist before starting is strongly advisable. This conversation requires clinical judgment specific to your diagnosis, treatment stage, and cancer type.

Pregnant or breastfeeding women: No safety data exists for NMN supplementation during pregnancy or lactation. In the absence of evidence, the precautionary approach is clear: NMN is not recommended during pregnancy or while breastfeeding. This is not a statement that it is harmful — it is a statement that the data to confirm safety in this population simply does not exist.

People taking warfarin or other anticoagulants: No study has looked at NMN alongside anticoagulant medications, so there is no evidence either way. As a precaution, if you are on warfarin or another blood thinner, tell your GP before adding NMN so your INR (clotting time) can be monitored during the first few weeks.

Children and adolescents: NMN has not been tested in paediatric populations. Children and teenagers have their own NAD+ biology that differs from adults, and there is no clinical rationale for supplementing this age group. NMN is not recommended for anyone under 18.

What We Don't Know Yet

Intellectual honesty requires naming the gaps in the evidence clearly, not glossing over them.

No long-term RCT data exists: Published randomised controlled trials of NMN in humans have mostly run for 12 weeks or less. Any effects — beneficial or potentially adverse — that might only emerge over years of continuous supplementation are not yet visible in the published literature.

No data on sustained very high doses: Short trials have found 1,200–1,250mg per day well tolerated for four to six weeks (Liao et al., 2021; Fukamizu et al., 2022), but there is no data on what happens at those doses over one, two or five years. Standard supplementation at 250 to 500mg per day is supported by a better evidence base than very high-dose protocols.

Limited diversity in trial populations: Published human trials have mostly enrolled specific populations — post-menopausal women, healthy older men, people with prediabetes. How NMN's safety profile extends to the full diversity of people who might supplement is not yet fully characterised.

These unknowns do not make NMN a dangerous supplement based on what we currently know. They are simply the honest frontiers of the science. NMN research is moving quickly — more trials, in more populations, over longer time frames are underway — and the picture will become clearer in the coming years.

Human Nutrients' Formulation: Why 500mg

Our NMN + Resveratrol formula delivers 500mg of NMN per two-capsule daily serving. This dose was selected deliberately based on the human trial data available at the time of formulation. 500mg represents the mid-range of doses showing measurable benefit in published human studies — sitting above the 250mg minimum effective dose and well below the 1,200–1,250mg per day tested in short-term safety studies.

Each serving also contains 600mg of 98% trans-resveratrol — the biologically active form of resveratrol that has been studied in peer-reviewed research for its role in activating sirtuin proteins. No interaction concerns between NMN and trans-resveratrol have been identified in the published literature. The two compounds work synergistically: NMN supplies the NAD+ that sirtuins require to function, while resveratrol helps activate those sirtuins — a relationship described as analogous to providing both fuel and a spark.

All batches of our NMN + Resveratrol are third-party tested before release. This testing confirms the identity and purity of the NMN and trans-resveratrol, verifies that the stated doses are accurate, and checks for the absence of heavy metals, pesticide residues, and microbial contamination. We make Certificates of Analysis available on request because we believe transparency about what is actually in your supplement is a baseline expectation, not a premium feature.

Frequently Asked Questions

Can you take too much NMN?

Short human trials have tested doses up to 1,250mg per day for four weeks without serious adverse events (Fukamizu et al., 2022). That said, no long-term data exists for very high doses. Standard supplementation sits at 250 to 500mg per day, which reflects the range tested most thoroughly in peer-reviewed human studies. Starting at the lower end and adjusting based on your response is a sensible approach. If you are taking high doses and experience GI discomfort, reducing the dose or splitting it across two servings (morning and midday) can help.

Is NMN safe for long-term use?

Most published randomised controlled trials have run for 12 weeks or less, so long-term safety data beyond that window does not yet exist in the peer-reviewed literature. Based on current evidence, NMN appears well tolerated, but it is honest to acknowledge that multi-year human trial data has not been published. For now, the evidence supports use at standard doses with regular check-ins with your healthcare provider as good practice.

Can I take NMN if I have cancer?

This is the most important caution associated with NMN supplementation. NAD+ plays a central role in cellular energy metabolism, and some research suggests that elevated NAD+ levels may support cancer cell proliferation. If you have a current cancer diagnosis or are in remission, you should discuss NMN supplementation with your oncologist before starting. This is not a blanket contraindication — it is a conversation that requires clinical judgement specific to your situation, cancer type, and treatment stage.

Does NMN interact with medications?

No drug interactions have been confirmed in clinical trials, but interaction studies have not been done either. If you take prescription blood thinners such as warfarin, consult your GP before adding NMN. People on other prescription medications should also mention NMN supplementation to their healthcare provider as a precaution, since comprehensive drug-interaction screening has not been conducted.

Third-Party Tested NMN + Resveratrol

500mg NMN, 98% Trans-Resveratrol, and BioPerine in one formula. Purity verified, potency confirmed. 60 capsules, £29.99 with free UK shipping on every order.

Shop NMN + Resveratrol →

This article is for informational purposes and does not constitute medical advice. Always consult your healthcare provider before starting any new supplement, particularly if you are pregnant, nursing, take prescription medications, or have an underlying health condition including any history of cancer.

References

  1. Yoshino M, Yoshino J, Kayser BD, et al. (2021). "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. doi:10.1126/science.abe9985. PubMed ↗
  2. Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. (2022). "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." NPJ Aging. doi:10.1038/s41514-022-00084-z. PubMed ↗
  3. Liao B, Zhao Y, Wang D, et al. (2021). "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." J Int Soc Sports Nutr. doi:10.1186/s12970-021-00442-4. PubMed ↗
  4. Fukamizu Y, Uchida Y, Shigekawa A, et al. (2022). "Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women." Sci Rep. doi:10.1038/s41598-022-18272-y. PubMed ↗
  5. Okabe K, Yaku K, Uchida Y, et al. (2022). "Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects." Front Nutr. doi:10.3389/fnut.2022.868640. PubMed ↗
  6. Kim M, Seol J, Sato T, et al. (2022). "Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study." Nutrients. doi:10.3390/nu14040755. PubMed ↗

How we choose and check sources: our editorial policy.

Related guides